28 April, 2025Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)
8 April, 2025Myricx Bio Announces Expansion of its Leadership Team to Advance NMTi-ADCs into Clinical Development
20 March, 2025Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219
18 March, 2025Sofinnova Partners exceeds target with €165M biotech acceleration fund, Europe’s largest, with strong Pharma support